Nick Diamond advises clients on a complex and evolving health policy and regulatory environment.

He has particular expertise in legislative and regulatory developments impacting health insurance and quality and payment reform.

Prior to joining Avalere, Nick led global market strategy in the healthcare and life sciences sectors at MarkLogic, a technology company based in Silicon Valley. Prior to MarkLogic, he held consulting roles at MITRE and Booz Allen Hamilton, where he advised the Centers for Medicare & Medicaid Services during implementation of the ACA.

Nick is also a member of the adjunct faculty at The George Washington University and an adjunct fellow at the Center for Public Health Initiatives at the University of Pennsylvania. He holds a JD from Charleston Law, a Master of Laws in global health law from Georgetown Law, an MA in bioethics from the University of Pennsylvania, and an undergraduate degree from Georgetown.

Authored Content


While the Department of Health & Human Services (HHS) did not intend for proposed changes to Anti-Kickback Statute (AKS) regulations to impact commercial market drug negotiations, some state laws may indirectly lead to commercial market implications.

With the number of measles cases rising across the country, FDA Commissioner Scott Gottlieb raised the prospect of federal intervention over exemptions to state-level immunization school-entry requirements. While not specifying what role the federal government would play, Gottlieb stated, “You could mandate certain rules about what is and isn’t permissible when it comes to allowing people to have exemptions.”

New research shows higher cost sharing for vaccines under Part D leads to fewer seniors getting vaccines. Immunization rates are higher for vaccines covered by Part D plans with lower cost sharing.